非在研机构 Ensoma, Inc.初创企业 |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
开始日期2022-06-24 |
申办/合作机构 Ensoma, Inc.初创企业 [+1] |
开始日期2021-06-16 |
申办/合作机构 Ensoma, Inc.初创企业 [+1] |
开始日期2020-10-05 |
申办/合作机构 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
急性淋巴细胞白血病 | 临床2期 | 美国 | Ensoma, Inc.初创企业 | 2021-06-16 |
多发性骨髓瘤 | 临床2期 | 美国 | 2020-10-05 | |
干细胞动员 | 临床2期 | 美国 | 2020-09-14 | |
造血干细胞移植 | 临床1期 | - | - | |
镰状细胞血症 | 药物发现 | 美国 | Ensoma, Inc.初创企业 | 2022-06-24 |
急性髓性白血病 | 药物发现 | 美国 | Ensoma, Inc.初创企业 | 2021-06-16 |
骨髓增生异常综合征 | 药物发现 | 美国 | Ensoma, Inc.初创企业 | 2021-06-16 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1期 | 一线 | - | (築獵構簾鹽繭衊夢簾窪) = some subjects experiencing grade 1/2 gastrointestinal AEs commonly observed with plerixafor and one grade 2 back pain with MGTA-145 at 0.075 mg/kg that resolved within minutes 簾憲簾衊觸簾顧製獵構 (鏇觸壓鏇廠範遞壓衊窪 ) 更多 | - | 2020-06-03 | ||
临床2期 | 25 | (艱願窪膚齋夢範鏇鏇醖) = At least 1 adverse event (AE) was seen in 90% of patients, 20% had grade 2 AEs (anemia, hypokalemia) and 20% had grade 3 AEs (worsening of baseline grade 3 anemia; hypocalcemia); all resolved. Acute & transient bone pain was seen in 40% of patients (back-2, hip-1, sternum-1), all grade 1, all on day 1, & resolved without intervention after 6 minutes (3-10) 齋鑰範壓製齋願醖廠築 (選夢糧顧選齋製顧衊願 ) | 积极 | 2021-05-28 | |||
临床1期 | - | - | (憲鏇廠顧鑰構鏇餘壓淵) = 淵壓顧膚窪鹽製襯積齋 選鹽鏇遞鏇廠壓淵範鬱 (窪淵構醖鹽餘壓襯窪窪 ) | - | 2021-03-14 | ||
临床2期 | 25 | 醖衊鹹夢壓鏇顧觸醖範(繭製淵築醖餘構觸膚壓) = 製衊構襯艱願鬱鏇顧襯 壓鬱淵繭壓顧鬱蓋鏇淵 (淵蓋壓選淵願遞憲鏇壓, 製築觸窪鹹觸齋鬱網艱 ~ 淵淵觸膚膚鏇鹽鏇繭願) 更多 | - | 2022-09-10 | |||
临床1期 | 一线 | - | (蓋製構顧選觸築艱膚衊) = MGTA-145 monotherapy was well tolerated with no significant adverse events (AEs). Grade 1, transient lower back pain that dissipated within minutes was reported. The combination of MGTA-145 with plerixafor was well tolerated, with some subjects experiencing grade 1/2 gastrointestinal AEs commonly observed with plerixafor and one grade 2 back pain with MGTA-145 at 0.075 mg/kg that resolved within minutes. 選製構餘鏇鏇壓選膚襯 (餘餘窪壓製鬱憲鏇夢糧 ) | 积极 | 2020-08-29 |